Form 4: Adaptive Biotechnologies CFO Sells Shares to Cover Tax Obligations

Adaptive Biotechnologies' Chief Financial Officer, Kyle Piskel, sold 248 shares of common stock to cover tax obligations related to the vesting of Restricted Stock Units (RSUs).

Summary

• Kyle Piskel, the Chief Financial Officer of Adaptive Biotechnologies, sold 248 shares of common stock on November 18, 2024.
• The sale was executed at a price of $4.98 per share.
• This transaction was not a discretionary trade but was mandated by the company's equity incentive plan to cover tax withholding obligations associated with the vesting of RSUs.
• Following the transaction, Mr. Piskel directly owns 154,330 shares of Adaptive Biotechnologies common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment.

Industry Context

This is a routine transaction for executives who receive equity compensation. It is common for companies to require sell-to-cover transactions to manage tax obligations related to vesting equity.

Comparison to Industry Standards

• Sell-to-cover transactions are a standard practice across publicly traded companies when executives vest equity awards.
• Many companies use similar mechanisms to manage tax obligations for their employees and executives.
• The number of shares sold is relatively small compared to the total holdings of the CFO, which is typical for these types of transactions.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Adaptive Biotechnologies, Kyle Piskel, CFO, stock sale, tax obligations, RSUs, equity incentive plan, Form 4